Impact of SOFT/TEXT in Premenopausal Breast Cancer

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.

Eric Jonasch, MD

FDA OKs T-DXd Companion Diagnostic in HER2-Low Metastatic Breast Cancer

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

The PATHWAY HER2 test has been approved to identify patients with HER2-ultralow metastatic breast cancer who may benefit from treatment with T-DXd.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

The PATHWAY HER2 test has been approved to identify patients with HER2-ultralow metastatic breast cancer who may benefit from treatment with T-DXd.

Shwetal Mehta, PhD

January 27th 2025

CAR T Therapy Shows Similar Efficacy, Safety in Multiple Myeloma Subgroups

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

$Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.$

Russ Conroy

Thermal Ablation Elicits OS Similar to Resection in CRC Liver Metastases

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

There were fewer adverse effects and no treatment-related deaths associated with thermal ablation vs surgical resection for patients with colorectal liver metastases.

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

There were fewer adverse effects and no treatment-related deaths associated with thermal ablation vs surgical resection for patients with colorectal liver metastases.

Related Content

Tim Cortese

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.

Eric Jonasch, MD

FDA OKs T-DXd Companion Diagnostic in HER2-Low Metastatic Breast Cancer

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

The PATHWAY HER2 test has been approved to identify patients with HER2-ultralow metastatic breast cancer who may benefit from treatment with T-DXd.

Shwetal Mehta, PhD

January 27th 2025

CAR T Therapy Shows Similar Efficacy, Safety in Multiple Myeloma Subgroups

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

$Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.$

Russ Conroy

Thermal Ablation Elicits OS Similar to Resection in CRC Liver Metastases

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.